Barclays’s iRadimed IRMD Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $1.44M | Sell |
14,981
-10,868
| -42% | -$1.09M | ﹤0.01% | 2542 |
|
|
2025
Q4 | $2.51M | Buy |
25,849
+1,862
| +8% | +$160K | ﹤0.01% | 2771 |
|
|
2025
Q3 | $1.71M | Sell |
23,987
-3,229
| -12% | -$215K | ﹤0.01% | 2995 |
|
|
2025
Q2 | $1.63M | Buy |
27,216
+6,501
| +31% | +$356K | ﹤0.01% | 3008 |
|
|
2025
Q1 | $1.09M | Sell |
20,715
-4,401
| -18% | -$247K | ﹤0.01% | 3058 |
|
|
2024
Q4 | $1.38M | Buy |
25,116
+1,342
| +6% | +$70.6K | ﹤0.01% | 3163 |
|
|
2024
Q3 | $1.2M | Buy |
23,774
+12,657
| +114% | +$584K | ﹤0.01% | 3244 |
|
|
2024
Q2 | $488K | Sell |
11,117
-3,635
| -25% | -$155K | ﹤0.01% | 3061 |
|
|
2024
Q1 | $649K | Sell |
14,752
-4,766
| -24% | -$211K | ﹤0.01% | 3430 |
|
|
2023
Q4 | $927K | Buy |
19,518
+8,862
| +83% | +$373K | ﹤0.01% | 3489 |
|
|
2023
Q3 | $473K | Buy |
10,656
+3,203
| +43% | +$149K | ﹤0.01% | 2839 |
|
|
2023
Q2 | $356K | Sell |
7,453
-2,049
| -22% | -$92.4K | ﹤0.01% | 2951 |
|
|
2023
Q1 | $374K | Buy |
9,502
+1,856
| +24% | +$67.5K | ﹤0.01% | 3459 |
|
|
2022
Q4 | $216K | Buy |
7,646
+2,587
| +51% | +$74K | ﹤0.01% | 3796 |
|
|
2022
Q3 | $152K | Sell |
5,059
-56
| -1% | -$1.95K | ﹤0.01% | 3349 |
|
|
2022
Q2 | $173K | Sell |
5,115
-13,273
| -72% | -$476K | ﹤0.01% | 3517 |
|
|
2022
Q1 | $825K | Buy |
18,388
+4,309
| +31% | +$199K | ﹤0.01% | 2551 |
|
|
2021
Q4 | $650K | Buy |
14,079
+5,104
| +57% | +$206K | ﹤0.01% | 3074 |
|
|
2021
Q3 | $301K | Buy |
8,975
+1,791
| +25% | +$60.9K | ﹤0.01% | 3421 |
|
|
2021
Q2 | $212K | Sell |
7,184
-4,117
| -36% | -$113K | ﹤0.01% | 3520 |
|
|
2021
Q1 | $290K | Buy |
11,301
+1,641
| +17% | +$39.2K | ﹤0.01% | 3518 |
|
|
2020
Q4 | $220K | Sell |
9,660
-509
| -5% | -$11.8K | ﹤0.01% | 3706 |
|
|
2020
Q3 | $216K | Sell |
10,169
-2,753
| -21% | -$61.8K | ﹤0.01% | 3796 |
|
|
2020
Q2 | $299K | Buy |
12,922
+8,553
| +196% | +$184K | ﹤0.01% | 3752 |
|
|
2020
Q1 | $93K | Sell |
4,369
-2,993
| -41% | -$71.3K | ﹤0.01% | 4854 |
|
|
2019
Q4 | $171K | Buy |
7,362
+2,010
| +38% | +$47K | ﹤0.01% | 5150 |
|
|
2019
Q3 | $113K | Buy |
5,352
+2,509
| +88% | +$51.2K | ﹤0.01% | 5388 |
|
|
2019
Q2 | $58K | Sell |
2,843
-53
| -2% | -$1.25K | ﹤0.01% | 6024 |
|
|
2019
Q1 | $82K | Buy |
2,896
+837
| +41% | +$21.9K | ﹤0.01% | 5515 |
|
|
2018
Q4 | $50K | Buy |
2,059
+721
| +54% | +$19.4K | ﹤0.01% | 5473 |
|
|
2018
Q3 | $50K | Buy |
1,338
+237
| +22% | +$6.39K | ﹤0.01% | 6081 |
|
|
2018
Q2 | $24K | Buy |
1,101
+1,087
| +7,764% | +$19.2K | ﹤0.01% | 6074 |
|
|
2018
Q1 | $0 | Buy |
+14
| New | +$199 | ﹤0.01% | 7186 |
|
|
2017
Q2 | – | Sell |
-1,319
| Closed | -$12K | – | 6776 |
|
|
2017
Q1 | $12K | Buy |
1,319
+1,152
| +690% | +$10.7K | ﹤0.01% | 6011 |
|
|
2016
Q4 | $2K | Buy |
167
+130
| +351% | +$1.4K | ﹤0.01% | 6349 |
|
|
2016
Q3 | $1K | Buy |
+37
| New | +$685 | ﹤0.01% | 6401 |
|
|
2016
Q1 | – | Sell |
-19,177
| Closed | -$537K | – | 6272 |
|
|
2015
Q4 | $537K | Buy |
19,177
+13,862
| +261% | +$392K | ﹤0.01% | 3156 |
|
|
2015
Q3 | $127K | Buy |
5,315
+5,261
| +9,743% | +$126K | ﹤0.01% | 4457 |
|
|
2015
Q2 | $1K | Buy |
+54
| New | +$986 | ﹤0.01% | 6916 |
|
Other funds holding IRMD
CCM
VCM
NTCM
Barclays's IRMD Position: Q1 2026 in Review
Barclays reduced its iRadimed (IRMD) stake by 42% in Q1 2026, selling an estimated $1.09M and leaving 14,981 shares worth $1.44M. The position accounts for ﹤0.01% of the portfolio, ranked #2542.
Barclays first reported a position in IRMD in Q2 2015 and has held it in 39 quarters since. The position peaked at $2.51M in Q4 2025. 228 funds tracked by Wall St. Rank hold IRMD as of Q1 2026.
- Barclays held 14,981 shares of iRadimed worth $1.44M as of Q1 2026.
- Barclays sold 10,868 iRadimed shares in Q1 2026, an estimated $1.09M.
- iRadimed made up ﹤0.01% of Barclays's portfolio in Q1 2026, its #2542 holding.
- Barclays first reported a position in iRadimed in Q2 2015 and has held it in 39 quarters since.
- Barclays's iRadimed position peaked at $2.51M in Q4 2025.
- 228 funds tracked by Wall St. Rank held iRadimed as of Q1 2026.
Based on Barclays's 13F filing for Q1 2026, filed 15 May 2026.